Skip to main content
SDGR
NASDAQ Life Sciences

Schrodinger Receives $57M Cash from Eli Lilly's Ajax Acquisition

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Health Tech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$17.39
Mkt Cap
$1.299B
52W Low
$10.945
52W High
$23.75
52W Position info
59% above low
Off High info
27% below high
Rel. Volume info
1.4× avg
Market data snapshot near publication time

SDGR sits 59% above its 52-week low of $10.945.

Summary

Schrodinger, Inc. announced it received a $57 million cash payment from Eli Lilly's acquisition of co-founded Ajax Therapeutics, with potential for additional milestone payments.


Key Events · M&A and Partnerships · SDGR

  • Cash Payment Received

    Schrodinger received approximately $57 million in cash from Eli Lilly's acquisition of Ajax Therapeutics, a company it co-founded.

  • Validation of Strategy

    This payment validates Schrodinger's drug discovery platform and its strategy of co-founding companies, providing significant non-dilutive capital.

  • Future Milestone Eligibility

    The company remains eligible to receive additional cash payments upon Ajax's achievement of specified clinical and regulatory milestones.


Analysis · SDGR · Life Sciences

This 8-K confirms Schrodinger's receipt of approximately $57 million in cash following Eli Lilly's acquisition of Ajax Therapeutics, a company co-founded by Schrodinger. This payment represents a significant non-dilutive capital inflow, validating Schrodinger's drug discovery platform and its strategy of co-founding companies. The company is also eligible for further milestone payments.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, SDGR was trading at $17.39 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $10.95 to $23.75. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

SDGR - Latest Insights

SDGR
Nov 05, 2026, 3:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $29.50
Real-time Price: $29.84 info
Change: +$0.340 (+1%) info
Market Cap: $2.217B info
SDGR
Nov 04, 2026, 4:08 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $31.44
Real-time Price: $29.84 info
Change: -$1.60 (-5%) info
Market Cap: $2.217B info
SDGR
Nov 04, 2026, 4:06 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $30.75
Real-time Price: $29.84 info
Change: -$0.9067 (-3%) info
Market Cap: $2.217B info
SDGR
Nov 04, 2026, 4:05 PM EST
Source: BusinessWire
Importance Score:
8
Price at Filing: $28.72
Real-time Price: $29.84 info
Change: +$1.12 (+4%) info
Market Cap: $2.217B info
SDGR
Sep 09, 2026, 7:00 AM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $20.03
Real-time Price: $29.84 info
Change: +$9.81 (+49%) info
Market Cap: $2.217B info